摘要 |
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1 (ABT) or therapeutic agent 2 (=ABT-333) or therapeutic agent 3 (=ABT-072) or therapeutic agent 4 (ABT), and an inhibitor of cytochrome P450 (e.g., ritonavir). |
申请人 |
ABBVIE INC. |
发明人 |
BERNSTEIN, BARRY, M.;MENON, RAJEEV, M.;KHATRI, AMIT;MENSING, SVEN;DUTTA, SANDEEP;COHEN, DANIEL, E.;PODSADECKI, THOMAS, J.;BRUN, SCOTT, C.;AWNI, WALID, M.;DUMAS, EMILY, O.;KLEIN, CHERI, E. |